Drugs used for treating GvHD

Read about the different drugs used to treat graft versus host disease (GvHD) and how they work.

How the drugs work

Most of these drugs work by damping down (suppressing) your immune system. This stops the donated cells (graft) from attacking your body (host). 

You are at a greater risk of getting an infection if you have GvHD, because it weakens your immune system. Treatments for GvHD further increase this risk.

Your doctor and nurses will keep a close eye on you. You should report any signs of infection as soon as you notice them so you can start any necessary treatment.

Drugs to treat GvHD

The drugs you take for GvHD depend on where you have it and how severe it is. Your health care team decide on the best type of treatment for you.

This is the most common and first treatment for GvHD. Steroids suppress your immune response and reduce inflammation.

Types of steroids for GvHD include:

  • prednisolone, which you take as a tablet
  • methylprednisolone, which you usually have as an injection into a vein
  • steroid creams to reduce skin GvHD
  • steroid eye drops for GvHD affecting the eye
  • budesonide for GvHD of the gut (digestive system Open a glossary item)

Once your GvHD is under control, your doctor will gradually reduce the dose. You might have steroids on their own, or with one of the other drugs or treatments listed on this page.

Ciclosporin is also known as Neoral, Deximune or Sandimmum. It works by reducing the number of T cells in your body. It comes as a capsule which you take daily or as a liquid that you drink.

You should try to avoid grapefruit or grapefruit juice when taking ciclosporin because it can interfere with how the drug works.

You will have regular blood tests to check for side effects to your kidneys or liver.

The common side effects of ciclosporin include:

  • feeling sick
  • indigestion
  • tiredness
  • dizziness
  • raised blood pressure
  • headaches
  • low levels of red blood cells (anaemia)
  • shaking hands (tremor)
  • kidney problems
  • excess growth of body and facial hair in women (hirsutism)
  • swollen gums

Tacrolimus is also known as Prograf, Modigraf and Advagraf. It suppresses your immune system to treat GVHD. It comes as capsules which you usually take twice a day. It is also available as a liquid that you drink. You can also have it by drip (intravenously).

The common side effects include:

  • shaking hands
  • high blood sugar
  • feeling sick and loss of appetite
  • diarrhoea
  • stomach pain
  • difficulty in sleeping

Your doctor may prescribe Protopic ointment (tacrolimus) if you have GVHD affecting the eyes.

This is also known as extracorporeal photopheresis or light therapy. Photopheresis can improve skin, liver and mouth GVHD. Your doctor may also suggest it for chronic GVHD of the lung.

You normally have photopheresis after other treatment hasn’t worked or has stopped working. Photopheresis is a complicated process and it may take up to 6 months before you see any real improvement in symptoms. Your doctor refers you to a skin specialist (dermatologist) if they think photopheresis may help your GVHD. You might need to go to a different centre that offers this treatment.

How you have it

To have the treatment your nurse will connect you to a machine by a drip. Your blood then goes through the machine, which separates off some of your white blood cells. Then the nurse gives you back your blood into your vein, minus the white blood cells.

The separated white blood cells are treated with a special drug and then exposed to ultraviolet light. This light activates the drug so that it is able to destroy the abnormal white blood cells. After this process your nurse gives back the treated white blood cells into your vein.

Each treatment takes between 3 and 4 hours, and you would usually have it every 2 weeks for between 6 and 12 months.

Side effects

Having this procedure does not hurt, but you will usually need to have a central line.

You might feel a bit weak or dizzy during or after the treatment. After the treatment your skin and eyes may be more sensitive to sunlight for about 24 hours, so you need to protect yourself from the sun and wear sunglasses.

Monoclonal antibodies are a type of targeted drug therapy.

They are made in the laboratory and are designed to target specific proteins on the surface of cells. You usually have them through a drip (intravenously) into your bloodstream. Several types of monoclonal antibody are being used to treat GvHD.

Alemtuzumab (Campath) works by targeting a protein on the surface of certain white blood cells and destroying them. This suppresses your immune system and helps prevent or treat GvHD.

Infliximab (Remicade) has been used to treat acute GvHD. It targets a type of chemical called a cytokine, which causes inflammation of body tissues. Infliximab binds with the cytokine to stop it from working.

Rituximab (Mabthera) acts on white blood cells called B cells. Doctors have been looking at whether B lymphocytes (another type of white blood cell) might also be involved in GvHD. These lymphocytes make antibodies which destroy foreign cells. Doctors have found that giving rituximab may help treat chronic GvHD. But we need more research to confirm this.

mTor inhibitors are a type of targeted drug therapy. 

mTOR is a type of protein that can make cells produce chemicals to trigger cell growth. So mTOR inhobitors stop cells from growing and dividing, and dampens the immune system. There are different types of mTOR inhibitor:

Sirolimus (Rapamune)

We know from research that sirolimus can help to prevent GvHD. Doctors may also use it to treat severe acute GvHD. It can also sometimes help to control chronic GvHD when steroids and ciclosporin are not working. 

You take it as tablets or a solution that you drink.

You should not have grapefruit or grapefruit juice when taking sirolimus because it can interfere with how the drug works. Rapamune liquid contains soya oil. Patients allergic to peanut or soya must not take this medicine.

You have regular blood tests to check your liver and kidney function.

Some of the most common side effects include:

  • low levels of platelets or red blood cells
  • a high temperature
  • high blood pressure
  • low levels of some important chemicals in the blood (potassium and phosphate)
  • pain in the abdomen, diarrhoea or constipation

You may have sirolimus with other drugs that suppress your immune system.

Everolimus

Everolimus is a drug that doctors may use instead of sirolimus. You take everolimus as a tablet.

Tyrosine kinase inhibitors (TKIs) are a type of targeted drug therapy.

They block messengers (enzymes) which send growth signals in cells. So they stop the cells growing and dividing. Imatinib (Glivec) is a type of TKI you may have for chronic GvHD, particularly if it's affecting the skin or lung. You take this as a tablet.

You might have another type of TKI called ibrutinib

Etanercept blocks a chemical called tumour necrosis factor (TNF) from causing damage to tissue. You have it as an injection under your skin.

Doctors are more likely to use it for acute GvHD. Etanercept may be particularly helpful for GvHD affecting the gut.

Side effects may include:

  • infection
  • high temperature
  • itchy skin
  • reaction around the injection site, such as pain, swelling and bruising

Thalidomide is another cancer growth blocker and works in different ways. As with the other drugs, it dampens the immune system.

Some research has shown that it can help to control chronic GvHD. Doctors don't use it very often and usually only if other treatments are not controlling the GvHD. You take thalidomide as a tablet. 

It is essential to avoid pregnancy while taking this drug and for a number of weeks afterwards

Mycophenolate is also known as CellCept. It is another drug doctors use to damp down your immune system. You take it by mouth as a tablet, capsule or liquid, usually twice a day.

The main side effects are diarrhoea, sickness and a higher risk of infections because it lowers your white blood count.

Pentostatin is a chemotherapy drug.

It can be used against acute or chronic GvHD because it breaks down the T cells. You have it through a drip in your arm (intravenously).

This drug puts you at a higher risk of infections. So, as with GvHD generally, look out for any signs of infection and report them immediately to your doctor.

Methotrexate is a type of chemotherapy drug. It stops T cells from dividing and so keeps the numbers down. You often have low doses of methotrexate after your transplant to try to prevent GvHD.

Newer drugs for GvHD include:

  • halofuginone, which is a drug that helps treat fibrosis caused by chronic GvHD
  • hydroxychloroquine. which is a drug used to treat malaria - it may be useful for chronic GvHD

Doctors are still looking at how well these treatments work for GvHD. Your doctor may offer you one of these treatments if other treatments have not controlled your GvHD.

  • Diagnosis and management of acute graft-versus-host disease
    F Dignan and others
    British Journal of Haematology, 2012. Volume 158, Issue 1, Pages 30–45

  • Diagnosis and management of chronic graft-versus-host disease
    F Dignan and others
    British Journal of Haematology, 2012. Volume 158, Issue 1, Pages 46-61

  • Organ-specific management and supportive care in chronic graft-versus-host disease
    F Dignan and others
    British Journal of Haematology, 2012. Volume 158, Issue 1, Pages 62-78

  • Graft-versus-host disease
    BMJ Best Practice website (Accessed November 2017)

  • Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation
    H Salmasian and others
    Cochrane Database Systematic Reviews, 20th January 2010

  • The information on this page is based on literature searches and specialist checking. We used many references and there are too many to list here. Please contact patientinformation@cancer.org.uk with details of the particular issue you are interested in if you need additional references for this information.

Last reviewed: 
08 Mar 2022
Next review due: 
08 Mar 2025

Related links